168 related articles for article (PubMed ID: 25054438)
1. 13th Annual Meeting of the Safety Pharmacology Society: focus on novel technologies and safety pharmacology frontiers.
Cavero I
Expert Opin Drug Saf; 2014 Sep; 13(9):1271-81. PubMed ID: 25054438
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative.
Cavero I; Holzgrefe H
Expert Opin Drug Saf; 2014 Jun; 13(6):745-58. PubMed ID: 24845945
[TBL] [Abstract][Full Text] [Related]
3. 14th Annual Meeting of the Safety Pharmacology Society: threading through scientific sessions for originality and novelty.
Cavero I
Expert Opin Drug Saf; 2015 Jun; 14(6):999-1008. PubMed ID: 25872620
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive in vitro Proarrhythmia Assay (CiPA): Pending issues for successful validation and implementation.
Cavero I; Guillon JM; Ballet V; Clements M; Gerbeau JF; Holzgrefe H
J Pharmacol Toxicol Methods; 2016; 81():21-36. PubMed ID: 27233533
[TBL] [Abstract][Full Text] [Related]
5. CiPA challenges and opportunities from a non-clinical, clinical and regulatory perspectives. An overview of the safety pharmacology scientific discussion.
Wallis R; Benson C; Darpo B; Gintant G; Kanda Y; Prasad K; Strauss DG; Valentin JP
J Pharmacol Toxicol Methods; 2018; 93():15-25. PubMed ID: 29958940
[TBL] [Abstract][Full Text] [Related]
6. Safety pharmacology methods and models in an evolving regulatory environment.
Pugsley MK; de Korte T; Authier S; Huang H; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Sep; 87():1-6. PubMed ID: 28461240
[TBL] [Abstract][Full Text] [Related]
7. 2012 Annual Meeting of the Safety Pharmacology Society: spotlight on targeted oncology medicines.
Cavero I
Expert Opin Drug Saf; 2013 Jul; 12(4):589-603. PubMed ID: 23668378
[TBL] [Abstract][Full Text] [Related]
8. Proarrhythmia liability assessment and the comprehensive in vitro Proarrhythmia Assay (CiPA): An industry survey on current practice.
Authier S; Pugsley MK; Koerner JE; Fermini B; Redfern WS; Valentin JP; Vargas HM; Leishman DJ; Correll K; Curtis MJ
J Pharmacol Toxicol Methods; 2017 Jul; 86():34-43. PubMed ID: 28223123
[TBL] [Abstract][Full Text] [Related]
9. 10th annual meeting of the Safety Pharmacology Society: an overview.
Cavero I
Expert Opin Drug Saf; 2011 Mar; 10(2):319-33. PubMed ID: 21314442
[TBL] [Abstract][Full Text] [Related]
10. Benchmarking safety pharmacology regulatory packages and best practice.
Lindgren S; Bass AS; Briscoe R; Bruse K; Friedrichs GS; Kallman MJ; Markgraf C; Patmore L; Pugsley MK
J Pharmacol Toxicol Methods; 2008; 58(2):99-109. PubMed ID: 18692579
[TBL] [Abstract][Full Text] [Related]
11. Cardiac voltage-gated ion channels in safety pharmacology: Review of the landscape leading to the CiPA initiative.
Huang H; Pugsley MK; Fermini B; Curtis MJ; Koerner J; Accardi M; Authier S
J Pharmacol Toxicol Methods; 2017 Sep; 87():11-23. PubMed ID: 28408211
[TBL] [Abstract][Full Text] [Related]
12. Safety pharmacology in 2022: Taking one small step for cardiovascular safety assay development but one giant leap for regulatory drug safety assessment.
Pugsley MK; Koshman YE; de Korte T; Authier S; Winters BR; Curtis MJ
J Pharmacol Toxicol Methods; 2022; 117():107206. PubMed ID: 35926772
[TBL] [Abstract][Full Text] [Related]
13. Biophysics and Molecular Biology of Cardiac Ion Channels for the Safety Pharmacologist.
Pugsley MK; Curtis MJ; Hayes ES
Handb Exp Pharmacol; 2015; 229():149-203. PubMed ID: 26091640
[TBL] [Abstract][Full Text] [Related]
14. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress.
Colatsky T; Fermini B; Gintant G; Pierson JB; Sager P; Sekino Y; Strauss DG; Stockbridge N
J Pharmacol Toxicol Methods; 2016; 81():15-20. PubMed ID: 27282641
[TBL] [Abstract][Full Text] [Related]
15. Recalibration of nonclinical safety pharmacology assessment to anticipate evolving regulatory expectations.
Pugsley MK; Authier S; Hayes ES; Hamlin RL; Accardi MV; Curtis MJ
J Pharmacol Toxicol Methods; 2016; 81():1-8. PubMed ID: 27343819
[TBL] [Abstract][Full Text] [Related]
16. CiPA: Ongoing testing, future qualification procedures, and pending issues.
Cavero I; Holzgrefe H
J Pharmacol Toxicol Methods; 2015; 76():27-37. PubMed ID: 26159293
[TBL] [Abstract][Full Text] [Related]
17. 2011 Annual Meeting of the Safety Pharmacology Society: an overview.
Cavero I
Expert Opin Drug Saf; 2012 Mar; 11(2):341-53. PubMed ID: 22339583
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update from a Cardiac Safety Research Consortium / Health and Environmental Sciences Institute / FDA Meeting.
Strauss DG; Gintant G; Li Z; Wu W; Blinova K; Vicente J; Turner JR; Sager PT
Ther Innov Regul Sci; 2019 Jul; 53(4):519-525. PubMed ID: 30157676
[TBL] [Abstract][Full Text] [Related]
19. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
[TBL] [Abstract][Full Text] [Related]
20. Safety pharmacology in focus: new methods developed in the light of the ICH S7B guidance document.
Pugsley MK; Curtis MJ
J Pharmacol Toxicol Methods; 2006; 54(2):94-8. PubMed ID: 16806993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
